WuXi PharmaTech released positive financial results for the first quarter of 2013, as revenues increased 11.7% to $132 million. All sectors of the company’s CRO/CMO business contributed to the climb. In remarks to analysts, Ge Li, the company's Chairman and CEO, conducted an interesting discussion of WuXi’s various business units, shedding light on each one’s performance and potential for growth in the next few years. More details....

Stock Symbol: (NYSE: WX)

Share this with colleagues:  

Hangzhou Nurotron Biotechnology has developed a less expensive cochlear implant, a medical device that allows severely deaf people to hear again. In China, the company offers a $16,000 implant, half the cost of the market-leading Australian import, a $32,000 device from Cochlear Ltd. Nurotron is headquartered in Hangzhou, where it also has a manufacturing facility. But its R&D operation is in Irvine, California, close to the home of its founder, Fan-Gang Zeng, PhD, the Director of the Center for Hearing Research at University of California at Irvine. More details....

Stock Symbol: (ASX: COH)

Share this with colleagues:  

ChinaBio^® Today recently had the chance to interview Dr. Jun Wang, a co-founder of China’s sequencing giant, BGI-Shenzhen. Dr. Wang was named Executive Director of the company at the young age of 32. The company works with many of the big pharma and has established several major international partnerships. The driving force behind these relationships, according to Dr. Wang, is always the science. “We are a dream-driven organization,” he says. The dream is the promise of genomic science to improve human life, and BGI seems willing to enter any partnership that will advance genomic science, even if it doesn’t necessarily represent a profit opportunity. More details....

Share this with colleagues: